Seattle, WA -- (SBWIRE) -- 09/19/2019 -- Biologics Market, by Product Type (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cell Therapy, and Gene Therapy)), by Application (Oncology, Infectious Diseases, Immunology, Autoimmune Diseases and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).
Request Sample Copy of This Report - https://www.coherentmarketinsights.com/insight/request-sample/2663
The global biologics market is expected to witness significant growth during the forecast period, owing to increasing product launches by key players such as Pfizer, Merck and Co., and GlaxoSmithKline (GSK). For instance, Pfizer has a robust pipeline for vaccines, biosimilars, biologics, and small molecules for 2019. The company has around 100 products in trial phase with 35 in phase 1, 28 in phase 2, 26 in phase 3, and 11 in the process of registration. The most recent one was for Pfizer's DAURISMO (glasdegib), which received the U.S. Food and Drug Administration (FDA) approval in November 2018. It was indicated for adult patients with newly-diagnosed acute myeloid leukemia for who intensive chemotherapy is not a viable option.
Moreover, the global biologics market is rapidly growing, owing to increasing number of U.S. FDA approvals for new biologics medicines indicated for the treatment of rare disease. For instance, in December 2017, GlaxoSmithKline (GSK) received the U.S. FDA approval for its biologic 'Nucala', which is indicated for the treatment of rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA). Moreover, the U.S. FDA approved around 46 more biologics in 2017.
Among regions, North America holds dominant position in the global biologics market. This is owing to high presence of major biopharmaceutical and pharmaceutical companies in the U.S. including Biogen Idec, Eli Lily and Compaby, AbbVie, GlaxoSmithKline, Amgen, Novartis, Johnson and Johnson, Sanofi, and Pfizer. Increasing product approvals from regulatory authorities is expected to boost the biologics market in North America. For instance, in 2018, the U.S. FDA's Center for Drug Evaluation and Research approved 59 novel drugs and biologics and were launched in the U.S.
Furthermore, Asia Pacific is expected to exhibit significant growth in the global biologics market, owing to increasing production of biosimilar products of biologics. A biosimilar is typically a biologic medical product, which is almost an identical copy of the original product that is manufactured by a different company. For instance, Biocon Ltd., an Indian biopharmaceutical company, launched two biosimilars namely CANMAb (trastuzumad) and Krabeva (bevacuzumab) in India in 2017 and 2017. These biosimilars were indicated for the treatment of several types of cancer.
Purchase Copy of This Report - https://www.coherentmarketinsights.com/insight/buy-now/2663
Global Biologics Market: Taxonomy
The global biologics market is segmented on the basis of product type, application, end user, and region.
By Product Type:
Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.
To Know More About Biologics Market - https://www.coherentmarketinsights.com/ongoing-insight/biologics-market-2663
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.